141184-48-7

Basic information

• Product Name: 1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)ETHANONE
• Synonyms: 1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)ETHANONE
• CAS NO: 141184-48-7
• Molecular Formula: C₁₄H₁₈O₃
• Molecular Weight: 234.29
• Mol File: 141184-48-7.mol

Chemical Properties

• Melting Point: 127-129 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 356.6±22.0 °C(Predicted)
• Appearance: /
• Density: 1.096±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)ETHANONE(141184-48-7)
• EPA Substance Registry System: 1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)ETHANONE(141184-48-7)

Safety Data

• Hazardous Substances Data: 141184-48-7(Hazardous Substances Data)

Usage

Chemical structure

Ketone derivative with a cyclopentyloxy group attached to the phenyl ring
The presence of a ketone group (C=O) and a cyclopentyloxy group (C5H9O) attached to a phenyl ring (C6H5) gives this compound its unique properties.

Applications

Organic synthesis and pharmaceutical research
This compound is used as a building block or intermediate in the production of various drugs and other organic compounds.

Potential uses

Development of pharmaceuticals, agrochemicals, and other materials
The structure of this compound suggests it may have applications in various industries, including pharmaceuticals and agriculture.

Further research

Necessary to fully understand and exploit the potential of this compound
Additional studies and experimentation are required to determine the specific properties, applications, and limitations of 1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)ETHANONE.

Solubility

Unknown, but may vary depending on the solvent used
The solubility of this compound is not provided, but it is likely to depend on the specific solvent used in a given context.

Stability

Unknown, but may be influenced by factors such as temperature, pH, and exposure to light
The stability of this compound is not provided, but it is likely to be affected by various factors, including temperature, pH, and light exposure.

Reactivity

Unknown, but may react with certain chemicals or under specific conditions
The reactivity of this compound is not provided, but it may react with certain chemicals or under specific conditions, such as in the presence of strong acids or bases.

Safety

Unknown, but should be handled with care and proper safety precautions
The safety profile of this compound is not provided, but it should be handled with care and proper safety precautions, such as wearing gloves and using eye protection, to minimize potential risks.

Upstream product

• 141184-47-6 1-methoxy-2-cyclopentyloxy-4-(1-hydroxyethyl)benzene 
• 621-59-0 isovanillin 
• 137-43-9 Cyclopentyl bromide 
• 67387-76-2 3-cyclopentyloxy-4-methoxybenzylaldehyde 
• 60-29-7 diethyl ether 
• 917-54-4 methyllithium 
• 144036-17-9 3-cyclopentyloxy-4-methoxy benzoic acid 
• 676-58-4 methylmagnesium chloride 
• 121-33-5 vanillin 

Downstream Products

• 894421-52-4 (E)-ethyl 3-(3-(cyclopentyloxy)-4-methoxyphenyl)but-2-enoate 
• 444797-39-1 3-(3-cyclopentyloxy-4-methoxy-phenyl)-2-methyl-butyric acid 
• 444797-38-0 3-(3-cyclopentyloxy-4-methoxy-phenyl)-2-methyl-butyric acid ethyl ester 
• 627501-09-1 1-[3-(cyclopentyloxy)-4-methoxyphenyl]butane-1,3-dione 
• 183588-68-3 2-chloro-1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethanone 
• 180992-27-2 [[1-(3-Cyclopentyloxy-4-methoxyphenyl)-1-ethenyl]oxy]trimethylsilane 
• 141184-49-8 3-cyclopentyloxy-4-methoxyacetophenone oxime 
• 141333-65-5 2-bromo-1-(3-(cyclopentyloxy)-4-methoxyphenyl)ethanone 
• 193749-00-7 C₁₈H₂₄O₄ 
• 1172617-18-3 6-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 

Relevant articles and documents

Design, synthesis, biological evaluation and structural characterization of novel GEBR library PDE4D inhibitors

Memory and cognitive functions depend on the cerebral levels of cyclic adenosine monophosphate (cAMP), which are regulated by the phosphodiesterase 4 (PDE4) family of enzymes. Selected rolipram-related PDE4 inhibitors, members of the GEBR library, have been shown to increase hippocampal cAMP levels, providing pro-cognitive benefits with a safe pharmacological profile. In a recent SAR investigation involving a subset of GEBR library compounds, we have demonstrated that, depending on length and flexibility, ligands can either adopt a twisted, an extended or a protruding conformation, the latter allowing the ligand to form stabilizing contacts with the regulatory domain of the enzyme. Here, based on those findings, we describe further chemical modifications of the protruding subset of GEBR library inhibitors and their effects on ligand conformation and potency. In particular, we demonstrate that the insertion of a methyl group in the flexible linker region connecting the catechol portion and the basic end of the molecules enhances the ability of the ligand to interact with both the catalytic and the regulatory domains of the enzyme.

Safety and Efficacy of New 3,6-diaryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine Analogs as Potential Phosphodiesterase-4 Inhibitors in NIH-3T3 Mouse Fibroblastic Cells

A novel series of potential phosphodiesterase-4 (PDE-4) inhibitors, 6-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, were developed. Different concentrations of the synthesized compounds were tested on cultured NIH-3T3 cells to determine their safety and efficacy in NIH-3T3 mouse fibroblastic cells in comparison with rolipram, a selective PDE-4 inhibitor. The viability of cells was determined by (3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazoliumbromide (MTT) assay. The PDE inhibition rate was measured indirectly by determination of concentrations of extracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) using enzyme-linked immunoassay technique. The results showed that all tested compounds caused a marked increase in the concentration of cAMP, whereas the concentration of cGMP stayed approximately unchanged. The cytotoxic IC50 of all synthesized compounds was approximately twofold greater than their required concentration for inhibition of PDE-4 (in terms of elevation of cAMP), and thus, these structures could be used to develop potent and safe inhibitors of PDE-4 enzyme.

INHIBITORS OF PHOSPHODIESTERASE TYPE-IV

The present invention relates to oxazine derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CMS disorders, AIDS, asthma, arthritis, bronchitis, chronic ob

INHIBITORS OF PHOSPHODIESTERASE TYPE-IV

The present invention relates to oxazine derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CMS disorders, AIDS, asthma, arthritis, bronchitis, chronic ob

Co-catalyzed reductive cyclization of azido and cyano substituted α,β-unsaturated esters with NaBH4: enantioselective synthesis of (R)-baclofen and (R)-rolipram

Sodium borohydride in combination with a catalytic amount of CoCl2 has been found to be an excellent catalytic system in reductive cyclizations of suitably substituted azido and cyano groups of α,β-unsaturated esters to afford γ and δ-lactams in high yields. The process has been demonstrated for the enantioselective synthesis of (R)-baclofen, (R)-rolipram, and (R)-4-fluorophenylpiperidinone, a key intermediate for (-)-paroxetine.

Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics

A new series of catechol hydrazines was synthesized and their structure-activity relationship (SAR) was analyzed for developing an effective phosphodiesterase 4 (PDE4) inhibitor as an anti-asthmatic drug candidate. Among the (E)-Analogues tested using in

6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same

A 6-phenyltetrahydro-1,3-oxazin-2-one derivative having the formula (I): wherein, R1is an unsubstituted or substituted C1to C8alkyl group; an unsubstituted or substituted C3to C7cycloalkyl group;, etc

Use of 2-phenylmorpholin-5-one derivatives

A 2-phenylmorpholin-5-one derivative having the formula (I): wherein R1 represents a C1 to C8 alkyl group, a C3 to C7 cycloalkyl group or an indanyl group, R2 represents a C1 to C4 alkyl group, R3 represents a hydrogen atom, a C1 to C5 alkyl group, etc., R4 represents a hydrogen atom, a C1 to C6 alkyl group, etc., R5, R6 represent a hydrogen atom, a C1 to C5 alkyl group, etc.,an optical isomer thereof or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof and a pharmaceutical composition containing the same.The above compound has a strong type IV phosphodiesterase (PDE) inhibitory activity and has bronchodilater and antiinflammatory effects.

Magnesium meerwein-ponndorf-verley-oppenauer reaction. the origin of an impurity in PDA-641 batches

An impurity in the initial scale-up batch of PDA-641 was identified and the pathway of its formation was established. The precursor of the impurity was formed by magnesium Meerwein-Ponndorf-Verley-Oppenauer reaction during the Grignard addition step. As a

Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents

There are disclosed compounds of the formula STR1 wherein R is STR2 R1 is hydrogen, lower alkyl or STR3 a is 1-3; b is 1-3; c is 0-2; X, Y and Z are each, independently, a bond, O, S. or NH, with the proviso that if one of X or Y is O, S or NH, the other must be a bond; R2 is amino, loweralkylamino, arylamino, loweralkoxy or aryloxy; R3 is hydrogen, halo, hydroxy, lower alkoxy, aryloxy, loweralkanoyloxy, amino, lower alkylamino, arylamino or loweralkanoylamino; R4 and R5 are each, independently hydrogen or lower alkyl; m is 0-4; n is 1-4; and o is 1-4; and, which by virtue of their ability to selectively inhibit an isoenzyme of 3':5'-cyclic AMP phosphodiesterase located in pulmonary smooth muscle tissue and inflammatory cells, are bronchodilatory and antinflammatory and so are useful in the treatment of acute and chronic bronchial asthma and associated pathologies.